// App-Quantinova.ai

POS0934 (2022) : EFFICACY OF UPADACITINIB ON PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT DEFINED BY INVESTIGATOR ASSESSMENT AND PRO-BASED CRITERIA: RESULTS FROM TWO PHASE 3 STUDIES

Researchers

Presenter

  • X. Baraliakos

Principal Investigators

  • R. Ranza

  • A. Ostor

  • F. Ciccia

  • L. Coates

  • S. Rednic

  • J. A. Walsh

  • T. Gao

  • A. Lertratanakul

  • I. H. Song

  • F. Ganz

  • K. Douglas

  • A. Deodhar

Medical Centers

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Matematica, Matematica, Universidade Federal de Uberlandia, Uberlandia, Brazil

  • Monash University and Emeritus Research, Melbourne, Australia

  • Universita Della Campania "Luigi Vanvitelli", Napoli, Italy

  • University of Oxford, Oxford, United Kingdom

  • Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Cluj, Romania

  • University of Utah School of Medicine, Salt Lake City, United States of America

  • 2George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City UT United States

  • AbbVie Inc, Immunology, Illinois, United States of America

  • AbbVie AG, Immunology, Baar, Switzerland

  • Oregon Health & Science University, Portland, United States of America

Locations

  • Germany

  • Brazil

  • Australia

  • Italy

  • United Kingdom

  • Romania

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved